AbbVie closes USD 10B multi-tranche senior notes offering to fund Apogee deal
ABBV•AbbVie completes $10 billion notes offering
AbbVie completed a $10 billion senior notes offering, including senior floating rate notes due 2028.
The deal included fixed-rate senior notes across eight maturities from 2028 to 2066, with coupons from 4.5% to 6.1%.
Proceeds are earmarked to fund part of the cash consideration for AbbVie’s planned acquisition of Apogee Therapeutics.
If the Apogee deal is terminated, AbbVie must redeem the floating-rate notes and fixed-rate notes due 2028-2038 at 101%.
